ArticlePhilosophical transactions of the Royal Society of London. Series B, Biological sciences2021
Veterinary endectocides for malaria control and elimination: prospects and challenges.
Article in Philosophical transactions of the Royal Society of London. Series B, Biological sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 25 citations in OpenAlex.
- Outdoor biting by malaria vectors: what are the options for intervention?Malaria journal · 2025Review
- Administration of ivermectin to cattle induced mortality, reduced fecundity and survivorship of Anopheles arabiensis in Ethiopia: an implication for expansion of vector control toolbox.Tropical medicine and health · 2024Article
- Effect of non-human hosts on the human biting rate of primary and secondary malaria vectors in Tanzania.Malaria journal · 2023Article
- Community perception of the autodissemination of pyriproxyfen for controlling malaria vectors in south-eastern Tanzania.Malaria journal · 2023Article
- Effects of larval exposure to sublethal doses of ivermectin on adult fitness and susceptibility to ivermectin in Anopheles gambiae s.s.Parasites & vectors · 2023Article
- Proof-of-concept study for a long-acting formulation of ivermectin injected in cattle as a complementary malaria vector control tool.Parasites & vectors · 2023Article
- Drug resistant parasites and fungi from a one-health perspective: A global concern that needs transdisciplinary stewardship programs.One health (Amsterdam, Netherlands) · 2022Article
- Broadening the range of use cases for ivermectin - a review of the evidence.Transactions of the Royal Society of Tropical Medicine and Hygiene · 2022Review
- Novel control strategies for mosquito-borne diseases.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Residual transmission is the persistence of malaria transmission after scale-up of appropriate vector control tools and is one of the key challenges for malaria elimination today. Although long associated with outdoor biting, other mosquito behaviours such as partly feeding upon animals contribute greatly to sustaining transmission. Peri-domestic livestock can be used as decoy to protect humans from blood-seeking vectors but this approach often leads to an increased malaria risk in a phenomenon known as zoopotentiation. Treating the said livestock with drugs capable of killing intestinal parasites as well as mosquitoes that feed upon them has the potential to tackle malaria through a previously unexplored mechanism. The advantages and challenges associated with this approach are briefly discussed here. Numerous references are purposely provided. This article is part of the theme issue 'Novel control strategies for mosquito-borne diseases'.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.